Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion.

Matsuda K, Makhay M, Johnson K, Iwaki Y.

J Asthma. 2012 Dec;49(10):1071-8. doi: 10.3109/02770903.2012.729631. Epub 2012 Oct 25.

PMID:
23094708
2.

Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma.

House SL, Matsuda K, O'Brien G, Makhay M, Iwaki Y, Ferguson I, Lovato LM, Lewis LM.

Respir Med. 2015 Oct;109(10):1268-73. doi: 10.1016/j.rmed.2015.08.003. Epub 2015 Aug 14.

PMID:
26324315
3.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
4.

Bedoradrine for treating asthma and chronic obstructive pulmonary disease.

Antoniu S.

Expert Opin Investig Drugs. 2014 Aug;23(8):1149-56. doi: 10.1517/13543784.2014.928284. Epub 2014 Jun 18. Review.

PMID:
24938936
5.

Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.

Kempsford R, Norris V, Siederer S.

Pulm Pharmacol Ther. 2013 Apr;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001. Epub 2012 Dec 8.

PMID:
23232038
6.

A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.

Singh D, Pujol H, Ribera A, Seoane B, Massana E, Astbury C, Ruiz S, de Miquel G.

BMC Pulm Med. 2014 Nov 14;14:176. doi: 10.1186/1471-2466-14-176.

7.

Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.

Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K.

Respir Med. 2013 Feb;107(2):180-95. doi: 10.1016/j.rmed.2012.10.025. Epub 2012 Dec 25.

8.

The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.

Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B.

Chest. 2012 Jul;142(1):119-27. doi: 10.1378/chest.11-2231.

PMID:
22241764
9.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
10.

Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.

Bjermer L, Rosenborg J, Bengtsson T, Lötvall J.

Ther Adv Respir Dis. 2013 Oct;7(5):264-71. doi: 10.1177/1753465813497527. Epub 2013 Aug 1.

PMID:
23907810
11.

A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.

Maleki-Yazdi MR, Beck E, Hamilton AL, Korducki L, Koker P, Fogarty C.

Respir Med. 2015 May;109(5):596-605. doi: 10.1016/j.rmed.2015.02.012. Epub 2015 Mar 3.

12.

Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.

Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D.

Respir Med. 2013 Oct;107(10):1558-67. doi: 10.1016/j.rmed.2013.05.016. Epub 2013 Jul 16.

13.

Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.

Kew KM, Karner C, Mindus SM, Ferrara G.

Cochrane Database Syst Rev. 2013 Dec 16;(12):CD009019. doi: 10.1002/14651858.CD009019.pub2. Review.

PMID:
24343671
14.

24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.

van Noord JA, Smeets JJ, Drenth BM, Rascher J, Pivovarova A, Hamilton AL, Cornelissen PJ.

Pulm Pharmacol Ther. 2011 Dec;24(6):666-72. doi: 10.1016/j.pupt.2011.07.006. Epub 2011 Aug 6.

PMID:
21839850
15.

Evaluation of efficacy and safety of budesonide delivered via two dry powder inhalers.

Kerwin EM, Pearlman DS, de Guia T, Carlsson LG, Gillen M, Uryniak T, Simonson SG.

Curr Med Res Opin. 2008 May;24(5):1497-510. doi: 10.1185/030079908X297240 . Epub 2008 Apr 16.

PMID:
18419878
16.

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.

Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, Sakamoto W, Adachi M.

PLoS One. 2015 Apr 20;10(4):e0124109. doi: 10.1371/journal.pone.0124109. eCollection 2015.

17.

Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.

Cates CJ, Wieland LS, Oleszczuk M, Kew KM.

Cochrane Database Syst Rev. 2014 Feb 6;(2):CD010314. doi: 10.1002/14651858.CD010314.pub2. Review.

PMID:
24504983
18.

Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.

Yang WH, Martinot JB, Pohunek P, Beier J, Magula D, Cameron R, Owen R, Higgins M.

Ann Allergy Asthma Immunol. 2007 Dec;99(6):555-61. doi: 10.1016/S1081-1206(10)60386-9.

PMID:
18219838
19.

Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma.

Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, Ruiz S.

Respir Med. 2014 Oct;108(10):1424-9. doi: 10.1016/j.rmed.2014.08.005. Epub 2014 Sep 8.

20.

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.

Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD007949. doi: 10.1002/14651858.CD007949.pub2. Review.

PMID:
26594816

Supplemental Content

Support Center